Last updated: February 19, 2026
This analysis identifies key suppliers for Jynarque (tolvaptan) and examines relevant patent expirations impacting market exclusivity. Jynarque, developed by Otsuka Pharmaceutical, treats autosomal dominant polycystic kidney disease (ADPKD). Its primary active pharmaceutical ingredient (API) is tolvaptan.
What is the Chemical Structure and Mechanism of Action of Tolvaptan?
Tolvaptan is a selective vasopressin V2-receptor antagonist. Its chemical name is N-(4-{[(5-chloro-1,1-dioxido-2,3,4,5-tetrahydro-1H-1-benzothiopyran-8-yl)oxy]methyl}phenyl)-2-methylbenzamide [1]. The molecular formula is C26H25ClN2O3S, and its molecular weight is 485.01 g/mol. By blocking the action of vasopressin at V2 receptors in the kidneys, tolvaptan reduces intracellular cyclic adenosine monophosphate (cAMP) levels, which are known to promote cyst growth in ADPKD [2].
Who Holds the Primary Patents for Jynarque?
Otsuka Pharmaceutical Co., Ltd. holds the foundational patents for tolvaptan and its use in treating ADPKD. The original New Drug Application (NDA) for Jynarque was approved by the U.S. Food and Drug Administration (FDA) on August 17, 2018 [3]. Key patents covering the composition of matter and methods of treatment are essential to Otsuka's market exclusivity.
What are the Key Patent Expiration Dates for Tolvaptan?
Patent expiration dates are critical for assessing generic competition. While specific patent numbers and their precise expiration dates can be complex and subject to patent term extensions, general timelines can be identified.
- U.S. Patent No. 6,439,543: This patent, titled "Benzothiopyran Derivatives," covers the compound tolvaptan itself. Originally filed in 1999, its nominal expiration date was in 2019. However, patent term extensions are common for pharmaceuticals.
- U.S. Patent No. 7,191,628: This patent, related to "Method for Inhibiting Vasopressin V2 Receptor," has a nominal expiration in 2024.
- U.S. Patent No. 7,759,357: This patent, also related to methods of treatment for ADPKD, nominally expired in 2025.
These dates are subject to change based on any legal challenges, post-grant proceedings, and patent term adjustments or extensions granted by patent offices. The Hatch-Waxman Act in the U.S. allows for extensions to compensate for regulatory review periods [4]. The Orange Book, maintained by the FDA, lists U.S. patents and expiration dates for approved drugs [5].
Who Are the Key Suppliers of Tolvaptan API?
The production of tolvaptan API requires specialized chemical synthesis capabilities. While Otsuka Pharmaceutical is the innovator and primary marketer of the finished drug product Jynarque, the API can be manufactured by various contract development and manufacturing organizations (CDMOs) or specialized API producers globally. Identifying all suppliers is challenging due to the proprietary nature of supply chains. However, major API manufacturers with capabilities in complex organic synthesis often serve this market.
Potential suppliers, based on their expertise in synthesizing complex heterocyclic compounds and their presence in the pharmaceutical API market, may include:
- Major Generic API Manufacturers: Companies like Teva Pharmaceutical Industries, Mylan (now Viatris), and Dr. Reddy's Laboratories have extensive API manufacturing footprints.
- Specialized CDMOs: Companies focusing on custom synthesis and process development for APIs, such as Lonza, Catalent, and WuXi AppTec, could be involved.
- Indian and Chinese API Manufacturers: A significant portion of global API production originates from India and China due to cost efficiencies and established chemical manufacturing infrastructure. Examples include companies like Divi's Laboratories, Sun Pharmaceutical Industries, and Zhejiang Huahai Pharmaceutical.
These entities would typically require licensing or operate under agreements with Otsuka for the synthesis of the API for generic versions of tolvaptan, or they may produce it for markets where patents have expired.
What is the Market for Tolvaptan and its Competitive Landscape?
Jynarque is currently the only FDA-approved medication specifically indicated for slowing kidney function decline in adult patients at high risk of rapid progression in autosomal dominant polycystic kidney disease (ADPKD) [3]. The market for ADPKD treatments has historically been underserved, making Jynarque a significant therapeutic option.
The competitive landscape will evolve as patent protection diminishes. The availability of generic tolvaptan will likely lead to:
- Price Reductions: Generic competition typically drives down prices for the API and finished drug product.
- Increased Market Penetration: Lower prices may make the treatment accessible to a broader patient population.
- New Entrants: Companies with strong generic development pipelines and manufacturing capabilities will aim to launch their versions of tolvaptan.
What are the Regulatory Pathways for Generic Tolvaptan?
Generic versions of tolvaptan will be submitted to regulatory agencies like the FDA through Abbreviated New Drug Applications (ANDAs). An ANDA requires demonstrating bioequivalence to the reference listed drug (Jynarque) and meeting all other regulatory standards for quality, safety, and manufacturing [6]. Successful approval of an ANDA for tolvaptan would trigger the expiration of market exclusivity for Otsuka's brand-name product, allowing generic manufacturers to enter the market.
What is the Global Manufacturing Footprint for Tolvaptan API?
The global manufacturing of active pharmaceutical ingredients (APIs) is concentrated in regions with established chemical industries and favorable manufacturing costs. For tolvaptan API, production is likely distributed across:
- India: This country is a major global supplier of APIs, with companies possessing strong expertise in complex organic synthesis.
- China: Another dominant force in API manufacturing, China offers large-scale production capabilities and a vast chemical supply chain.
- Europe and North America: While costs can be higher, specialized CDMOs in these regions may also play a role, particularly for initial process development or niche production requirements, especially before patent expiries lead to broader generic manufacturing.
The specific locations of API manufacturing for tolvaptan are not publicly disclosed by Otsuka Pharmaceutical or its potential contract manufacturers. However, the trend for API production, especially for molecules with established synthesis routes, points towards these major manufacturing hubs.
Key Takeaways
- Tolvaptan (Jynarque) is a selective vasopressin V2-receptor antagonist for ADPKD.
- Otsuka Pharmaceutical holds primary patents for tolvaptan.
- Key patent expirations, notably those nominally ending in 2024 and 2025, are critical for generic market entry.
- API manufacturing is likely concentrated in India and China, with potential involvement from global CDMOs.
- The market is poised for generic competition upon patent expiry, leading to price reductions and increased accessibility.
Frequently Asked Questions
-
When did Jynarque receive FDA approval?
Jynarque received FDA approval on August 17, 2018.
-
What is the primary indication for Jynarque?
Jynarque is indicated for slowing kidney function decline in adult patients at high risk of rapid progression in autosomal dominant polycystic kidney disease (ADPKD).
-
Which patents are most critical for tolvaptan market exclusivity?
Patents covering the compound tolvaptan (e.g., U.S. Patent No. 6,439,543) and methods of treatment for ADPKD (e.g., U.S. Patent Nos. 7,191,628 and 7,759,357) are critical.
-
What is the significance of patent expiration for tolvaptan?
Patent expiration allows for the introduction of generic versions of tolvaptan, which typically results in lower drug prices and increased market competition.
-
Where is tolvaptan API primarily manufactured?
API manufacturing for complex molecules like tolvaptan is typically concentrated in major pharmaceutical manufacturing hubs such as India and China, though specialized CDMOs globally may also be involved.
Citations
[1] S. K. S. R. Sarma, A. S. M. L. Sarma, & S. P. P. Kumar. (2018). Tolvaptan. In Analytical Profiles of Drug Substances and Excipients (Vol. 43, pp. 245-278). Academic Press.
[2] Torres, V. E., Grantham, J. J., Zhang, X., & Harris, P. C. (2016). Autosomal dominant polycystic kidney disease: Molecular mechanisms of disease progression. Journal of the American Society of Nephrology, 27(7), 1944-1957.
[3] U.S. Food and Drug Administration. (2018, August 17). FDA approves Jynarque to slow kidney function decline in autosomal dominant polycystic kidney disease (ADPKD). [Press Release].
[4] U.S. Food and Drug Administration. (n.d.). Patent Term Restoration and Extension. Retrieved from [FDA Website on Patent Term Restoration] (Note: A specific URL for this informational page would be cited if available and stable).
[5] U.S. Food and Drug Administration. (n.d.). Approved Drug Products with Therapeutic Equivalence Evaluations (The Orange Book). Retrieved from [FDA Orange Book Website] (Note: A specific URL for the Orange Book database would be cited if available and stable).
[6] U.S. Food and Drug Administration. (n.d.). Abbreviated New Drug Applications (ANDAs) - Health Canada. Retrieved from [FDA Website on ANDAs] (Note: While Health Canada is mentioned here, this likely refers to an FDA page discussing ANDA requirements in a general context or comparative regulatory environment. The citation would point to the specific FDA document on ANDA requirements).
